Beyond market averages, investors seeking exceptional growth focus on the art of stock selection. The right picks can significantly contribute to the expansion of your wealth.
As of close of business last night, Zentalis Pharmaceuticals Inc’s stock clocked out at $2.94, down -9.54% from its previous closing price of $3.25. In other words, the price has decreased by -$9.54 from its previous closing price. On the day, 0.92 million shares were traded. ZNTL stock price reached its highest trading level at $3.29 during the session, while it also had its lowest trading level at $2.89.
Ratios:
To gain a deeper understanding of ZNTL’s stock, we examine its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 7.76 and its Current Ratio is at 7.76. In the meantime, Its Debt-to-Equity ratio is 0.16 whereas as Long-Term Debt/Eq ratio is at 0.15.
On June 20, 2024, UBS Downgraded its rating to Neutral which previously was Buy and also lowered its target price recommendation from $28 to $5.
Insider Transactions:
Investing in insider trades can also provide an investor with insight into how management views future stock prices. A recent insider transaction in this stock occurred on Dec 31 ’25 when WALTERS GROUP bought 6,459,973 shares for $1.20 per share. The transaction valued at 7,751,968 led to the insider holds 13,509,973 shares of the business.
Matrix Capital Management Comp sold 7,500,000 shares of ZNTL for $9,975,000 on Dec 15 ’25. The 10% Owner now owns 6,459,973 shares after completing the transaction at $1.33 per share. On Apr 30 ’25, another insider, Myers Scott Dunseth, who serves as the Director of the company, bought 21,000 shares for $1.40 each. As a result, the insider paid 29,373 and bolstered with 281,192 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, ZNTL now has a Market Capitalization of 190367296 and an Enterprise Value of -27822710. For the stock, the TTM Price-to-Sale (P/S) ratio is 7.91 while its Price-to-Book (P/B) ratio in mrq is 0.84. Its current Enterprise Value per Revenue stands at -1.036 whereas that against EBITDA is 0.183.
Stock Price History:
The Beta on a monthly basis for ZNTL is 1.70, which has changed by 0.22500002 over the last 52 weeks, in comparison to a change of 0.15024745 over the same period for the S&P500. Over the past 52 weeks, ZNTL has reached a high of $3.95, while it has fallen to a 52-week low of $1.01. The 50-Day Moving Average of the stock is 62.83%, while the 200-Day Moving Average is calculated to be 91.77%.
Shares Statistics:
It appears that ZNTL traded 1.32M shares on average per day over the past three months and 2778000 shares per day over the past ten days. A total of 72.25M shares are outstanding, with a floating share count of 48.69M. Insiders hold about 32.61% of the company’s shares, while institutions hold 56.00% stake in the company. Shares short for ZNTL as of 1767139200 were 4111105 with a Short Ratio of 3.11, compared to 1764288000 on 5129111. Therefore, it implies a Short% of Shares Outstanding of 4111105 and a Short% of Float of 7.1.
Earnings Estimates
The stock of Zentalis Pharmaceuticals Inc (ZNTL) is currently drawing attention from 7.0 analysts actively involved in the ongoing evaluation and rating process.The consensus estimate for the next quarter is -$0.44, with high estimates of -$0.38 and low estimates of -$0.55.
Analysts are recommending an EPS of between -$1.37 and -$1.95 for the fiscal current year, implying an average EPS of -$1.76. EPS for the following year is -$1.6, with 7.0 analysts recommending between -$1.05 and -$2.27.
